Skip to Content

Amplify Treatments, Testing and Adv ETF GERM

Medalist Rating as of | See Amplify Investment Hub

Morningstar’s Analysis GERM

Will GERM outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Amplify Treatments, Testing and Adv ETF’s management team is rated Average, but a solid investment process still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the second-lowest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings GERM

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 53.6
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Moderna Inc

7.64 694,417
Healthcare

Quest Diagnostics Inc

7.20 654,079
Healthcare

BioNTech SE ADR

6.47 587,981
Healthcare

Alnylam Pharmaceuticals Inc

6.31 573,690
Healthcare

Laboratory Corp of America Holdings

6.10 554,388
Healthcare

ImmunityBio Inc Ordinary Shares

4.78 434,452
Healthcare

QuidelOrtho Corp

3.85 350,026
Healthcare

Immunocore Holdings PLC ADR

3.82 347,014
Healthcare

Dynavax Technologies Corp

3.80 345,030
Healthcare

Bio-Rad Laboratories Inc Class A

3.74 340,090
Healthcare